Catherine Henry
Associate Director, Preclinical R&D Cullinan Oncology
Catherine Henry, PhD, is an associate director at Cullinan Therapeutics, where she is the program lead of the preclinical HPK1 degrader program. Prior to joining Cullinan, Catherine completed her PhD in Biological Engineering in Angela Koehler’s lab at MIT. Her thesis focused on developing high-throughput platforms to identify the targets of small molecules.
Seminars
Monday 27th October 2025
Developing a Screening Funnel for Targeted Protein Degraders
11:30 am
- Establishing high-throughput assays for on and off-target degradation
- Applying learnings from drug discovery efforts in the “beyond rule of 5” chemical space to predict and assess oral bioavailability
- Profiling PK/PD in vivo and conducting lead optimization studies (Tier 2 ADME, selectivity, and cross-species DMPK)
